These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 25757)

  • 21. Labetalol: an alpha- and beta-blocker.
    Conner CS
    Drug Intell Clin Pharm; 1983; 17(7-8):543-4. PubMed ID: 6135593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects.
    Mehta J; Cohn JN
    Circulation; 1977 Feb; 55(2):370-5. PubMed ID: 12880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol.
    Richards DA; Tuckman J; Prichard BN
    Br J Clin Pharmacol; 1976 Oct; 3(5):849-55. PubMed ID: 9968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of blood pressure angiotensin II and aldosterone concentrations during treatment of severe hypertension with intravenous labetalol: comparison with propranolol.
    Trust PM; Rosei EA; Brown JJ; Fraser R; Lever AF; Morton JJ; Robertson JI
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):799-803. PubMed ID: 791333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of beta-adrenoceptor blockers and calcium antagonists in hypertension.
    Doyle AE
    Hypertension; 1983; 5(4 Pt 2):II103-8. PubMed ID: 6134671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of an alpha- and beta-adrenoceptor-blocking agent (labetalol) on haemodynamics in hypertension.
    Bahlmann J; Brod J; Hubrich W; Cachovan M; Pretschner P
    Br J Clin Pharmacol; 1979; 8(Suppl 2):113S-117S. PubMed ID: 526390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Haemodynamic effects of combined alpha- and beta-adrenoreceptor blockade after intravenous labetalol in hypertensive patients at rest and during exercise.
    Koch G
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):725-8. PubMed ID: 10950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparative effects of an alpha 1 and beta 1-2 blocker (labetalol) and a beta-1 blocker (atenolol) in the hypertensive patient].
    Sassard J; Zech PY; Pozet N; Cuisinaud G; Vincent M
    J Pharmacol; 1983; 14 Suppl 2():121-9. PubMed ID: 6355664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of the haemodynamic effects of labetalol in man.
    Cohn JN; Mehta J; Francis GS
    Br J Clin Pharmacol; 1982 Jun; 13(1 Suppl):19S-26S. PubMed ID: 7093099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Labetalol.
    Carter BL
    Drug Intell Clin Pharm; 1983 Oct; 17(10):704-12. PubMed ID: 6354658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous labetalol in hypertensive patients treated with beta-adrenoreceptor-blocking drugs.
    Pearson RM; Havard CW
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):795-8. PubMed ID: 10953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The relationships between the cardiovascular effects, alpha- and beta-adrenoceptor blocking actions and plasma concentration of labetalol in doca hypertensive rats.
    Drew GM; Hilditch A; Levy GP
    Clin Exp Hypertens (1978); 1979; 1(5):597-611. PubMed ID: 42517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists.
    van Zwieten PA
    Drugs; 1993 Apr; 45(4):509-17. PubMed ID: 7684671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A controlled trial of labetalol (Trandate), propranolol and placebo in the management of mild to moderate hypertension.
    Pugsley DJ; Nassim M; Armstrong BK; Beilin L
    Br J Clin Pharmacol; 1979 Jan; 7(1):63-8. PubMed ID: 367410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antihypertensive effect of labetalol, a new alpha- and beta-adrenergic blocking agent.
    Hansson L; Hänel B
    Int J Clin Pharmacol Biopharm; 1976 Oct; 14(3):195-8. PubMed ID: 12115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The combined alpha- and beta-adrenergic blocker labetalol and propranolol in the treatment of high blood pressure: similarities and differences.
    Weber MA; Drayer JI; Kaufman CA
    J Clin Pharmacol; 1984; 24(2-3):103-12. PubMed ID: 6143765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The alpha- and beta-adrenoceptor blocking potencies of labetalol and its individual stereoisomers in anaesthetized dogs and in isolated tissues.
    Brittain RT; Drew GM; Levy GP
    Br J Pharmacol; 1982 Sep; 77(1):105-14. PubMed ID: 6127131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Labetalol in the treatment of angina pectoris.
    Kanto JH
    Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):166-74. PubMed ID: 2881899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of intravenous labetalol on blood pressure, angiotensin II and aldosterone in hypertension: comparison with propranolol.
    Rosei EA; Trust PM; Brown JJ; Fraser R; Lever AF; Morton JJ; Robertson JI
    Clin Sci Mol Med Suppl; 1976 Dec; 3():497s-499s. PubMed ID: 1071671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of the R, R-isomer of labetalol, SCH 19927, in isolated tissues and in spontaneously hypertensive rats during a repeated treatment.
    Monopoli A; Bamonte F; Forlani A; Ongini E; Parravicini L
    Arch Int Pharmacodyn Ther; 1984 Dec; 272(2):256-63. PubMed ID: 6151824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.